A novel approach to in vivo receptor binding experiments is presented which allows direct quantitation of binding site densities. The method is based on an equilibrium model of tracer uptake and is designed to produce a static distribution proportional to receptor density and to minimize possible confounding influences of regional blood flow, blood-brain barrier permeability, and nonspecific binding. This technique was applied to the measurement of regional muscarinic cholinergic receptor densities in rat brain using [3H]scopolamine. Specific in vivo binding of scopolamine demonstrated saturability, a pharmacologic profile, and regional densities which are consistent with interaction of the tracer with the muscarinic receptor. Estimates of receptor density obtained with the in vivo method and in vitro measurements in homogenates were highly correlated. Furthermore, reduction in striatal muscarinic receptors following ibotenic acid lesions resulted in a significant decrease in tracer uptake in vivo, indicating that the correlation between scopolamine distribution and receptor density may be used to demonstrate pathologic conditions. We propose that the general method presented here is directly applicable to investigation of high affinity binding sites for a variety of radioligands.
A novel approach to in vivo receptor binding experiments is presented which allows direct quantitation of binding site densities. The method is based on an equilibrium model of tracer uptake and is designed to produce a static distribution proportional to receptor density and to minimize possible confounding influences of regional blood flow, blood-brain barrier permeability, and nonspecific binding. This technique was applied to the measurement of regional muscarinic cholinergic receptor densities in rat brain using [3H] scopolamine. Specific in vivo binding of scopolamine demonstrated saturability, a pharmacologic profile, and regional densities which are consistent with interaction of the tracer with the muscarinic receptor. Estimates of receptor density obtained with the in vivo method and in vitro measurements in homogenates were highly correlated. Furthermore, reduction in striatal muscarinic receptors following ibotenic acid lesions resulted in a significant decrease in tracer uptake in vivo, indicating that the correlation between scopolamine distribution and receptor density may be used to demonstrate pathologic conditions. We propose that the general method presented here is directly applicable to investigation of high affinity binding sites for a variety of radioligands.
Extensive attempts in the past to demonstrate the in vivo distribution of radiolabeled drugs within the central nervous system encompassed a variety of approaches. The goals of initial studies were to demonstrate the regional distributions of labeled drugs and neurotoxins at their presumed sites of action in the brain (Roth and Barlow, 1961) . With the development of receptor binding techniques, a second application of in vivo tracer distribution emerged: tracer distribution experiments were employed to reveal the anatomic localization of high affinity drug-binding sites previously detected in tissue homogenates (Yamamura et al., 1974; Hollt et al., 1977; Chang and Snyder, 1978; Kuhar et al., 1978) . Autoradiographic localization of drug binding revealed anatomic detail at the light (Kuhar and Yamamura, 1976; Murrin et al., 1977; Murrin and Kuhar, 1979) and electron microscopic (Kuhar et al., 1981) (Eckelman et al., 1979 (Eckelman et al., , 1984 Raichle, 1979; Wagner et al., 1983 et al. (1974) following bolus injection of the tracer into the tail vein of the rat. Attempts in this laboratory as well as in those of others (Drayer et al., 1982; Vora et al., 1983) to extend these findings to lower drug doses compatible with eventual clinical imaging protocols have demonstrated poorer correlation between receptor density and tissue radioactivity and have prompted a re-examination of the design of in vivo receptor binding experiments.
In this report we describe a quantitative approach to in vivo measurement of regional receptor densities based on the equilibrium distribution of radiolabeled tracers. The feasibility of this approach has been examined using [3H] 
This correction for intravascular tracer is frequently ignored, since brain blood volumes are estimated to be 1 to 5% (Kuhl et al., 1980; Cremer and Seville, 1983) . It has been omitted from analysis of the data in the present study since tissue tracer levels were found to be greater than or equal to blood tracer levels at all times examined.
The extravascular tracer consists of three components: LE, N& and SE, representing free, nonspecific, and specifically bound tracer, respectively.
If it is assumed that free and nonspecifically bound tracer concentrations at equilibrium are proportional to the plasma ligand concentration, an apparent tissue-to-blood partition coefficient, X, may be defined:
and, by substitution into equation 2 and rearrangement of terms:
s, = c, -h cg (4) Equation 4 can be used to determine the amount of tracer in tissue specifically bound to the receptor site at equilibrium when CE and CB are measured and the local value of X is known. At saturating ligand concentrations, the local tissue density of binding sites may be estimated by this method directly. The regional values of X may be determined from animals in which specific binding has been eliminated either by pretreatment with a saturating dose of a long-acting competitor or by reducing the specific activity of a saturating dose of the radioactive ligand so that SE is small compared to CE, in which cases: was suspended in olive oil at a concentration of 20 mg/ml and administered by intramuscular injection. Striutal lesions. Unilateral striatal lesions were produced by stereotaxic injection of the excitatory neurotoxin ibotenic acid. Animals were anesthetized with diethyl ether and mounted in a stereotaxic frame with reference planes according to the atlas of KBnig and Klippel (1963) . Twenty micrograms of ibotenic acid were injected in 1 ~1 over a period of 8 min through a 30 gauge steel cannula positioned at the following coordinates: 1.0 mm anterior to the bregma, 2.6 mm lateral to the midline, and 5.5 mm below the dura. The cannula was left in place for an additional 2 min following the injection to minimize reflux of ibotenate up the cannula track.
Tissue dissection. Animals were killed by decapitation at various intervals following initiation of tracer infusion. Brains were dissected, and a coronal slice approximately 3 mm thick extending from the optic chiasm rostrally to the midpoint of the olfactory tubercles was removed. This slice served as a source for striatal as well as cortical tissue samples. Additional samples of cortex were obtained from the rostra1 poles of the frontal lobes. The hippocampal formation was removed by blunt dissection of the overlying parietal and temporal cortex and subsequent separation from the underlying diencephalon. The cerebellum was separated from the brainstem by severing the cerebellar peduncles. The samples from left and right hemispheres of each animal were pooled and resulted in the following tissue yields: striatum, 40 to 60 mg; frontoparietal cortex (areas 2, 3, 4, 6, 8, and 10 of Brodmann), 100 to 150 mg; hippocampus (including dentate gyrus), 100 to 140 mg; and cerebellum (including white matter and deep nuclei), 200 to 250 mg. Samples were wrapped in foil and stored at -70°C in sealed plastic bags to minimize dessication. Plasma was obtained by centrifugation of heparinized blood taken from the arterial catheter at the end of the infusion period.
Determination of fH]scopolamine and metabolites. Brain samples were weighed, homogenized in 10 vol of 80% ethanol, and centrifuged at 15,000 X g for 10 min. Plasma samples were mixed with 3 vol of 95% ethanol and centrifuged. Aliquots of the ethanol supernatants were analyzed for total radioactivity and for nonvolatile activity following drying at 80°C. Scopolamine content of the nonvolatile fraction was determined by thin layer chromatography. Aliquots of the ethanol supernatants were concentrated by vacuum dessication and chromatographed with carrier scopolamine on silica gel plates with fluorescent indicator using the solvent system described above. Scopolamine was located by fluorescence quench and quantitated by scintillation counting. Extraction of activity from tissue and plasma into the ethanol supernatant was essentially complete. Recovery of [3H]scopolamine standards following addition to tissue blanks was greater than 80%.
Results
In vitro scopolamine binding. In agreement with previous studies (Kloog and Sokolovsky, 1978) , equilibrium binding of scopolamine to homogenates of rat forebrain was consistent with ligand interaction with a single population of binding sites (I& = 0.38 f 0.01 nM; B,, = 0.81 + 0.04 fmol/pg of protein, 65 + 1 fmol/mg of tissue; n = 3; see Fig. 1 ). Specific binding of [3H]scopolamine was completely displaced by addition of 1 PM nonradioactive scopolamine or 100 nM QNB. In similar fashion, specific binding of [3H]QNB was displaced by unlabeled scopolamine, suggesting identity of the high affinity binding sites for the two ligands.
In vivo scopolamine distribution. The time course of accumulation of scopolamine and metabolites in brain was examined following administration of 150 &i/kg of [3H]scopolamine at specific activities of 250 and 0.25 Ci/mol (6 X 10m7 and 6 x 10m4 mol/kg, respectively) over a period of 240 min. Plasma scopolamine concentrations produced by these doses were 23 + 4 nM and 20 + 2 PM, respectively.
Volatile radioactivity increased linearly with time in all tissues studied (Fig. 2) . Nonvolatile metabolites contributed significantly to plasma radioactivity but accounted for only 10% of the activity in the cerebellum following the high specific activity tracer infusion, and even less in other brain regions. In low specific activity experiments, volatile radioactivity and labeled metabolites accounted for a greater portion of total recoverable brain radioactivity, whereas the distribution of counts in plasma was qualitatively similar to that observed at 250 Ci/mol. No regional differences were observed in the distribution or time course of accumulation of labeled metabolites of [3H]scopolamine.
[3H]Scopolamine itself showed wide regional differences in its distribution following infusion at 250 Ci/mol (Fig. 3A) . In contrast, its distribution following infusion at 0.25 Ci/mol was relatively homogeneous and appears to reflect primarily nonspecific tracer uptake (Fig. 3B ). Blood and regional brain tracer concentrations determined from this latter group of animals were used to determine regional values of X as described previously (see "Theory," equation 5) and resulted in the following estimates: striatum, 1.5; cortex, 1.7; hippocampus, cerebellum, 1.1. Total scopolamine uptake in the group receiving the high specific activity tracer was corrected for nonspecific binding using plasma tracer levels and the regional values of X according to equation 4 (Fig. 3C ). Although this correction is not rigorously applicable in the absence of tracer equilibration, the resulting underestimation of specific binding at early times is likely to be small since nonspecific uptake (Fig. 3B) is rapid compared to the time course of total uptake (Fig. 3A) . Specific binding of scopolamine reached equilibrium rapidly in the cerebellum, appeared to approach asymptotic values in hippocampus and cerebral cortex, and continued to increase in almost linear fashion in the striatum during the 240-min tracer infusion. Comparison of specific in uiuo scopolamine binding at 240 min with the regional distribution of muscarinic receptors determined in uitro with [3H]QNB demonstrates close correlation between the two parameters ( Table I) . Distribution of scopolamine 240 min after establishment of constant plasma tracer levels was additionally examined at specific activities of 125 and 16 Ci/mol (1.2 X lO-'j and 9.4 X 10v6 mol/kg, respectively; Fig. 4 The variability associated with measurement of displacement of specific binding in cerebellum reflects the lower levels of total isotope uptake, as well as the lower ratio of specific to nonspecific binding in this region.
Three weeks after unilateral striatal ibotenic acid lesions, the accumulation of [3H]scopolamine in the lesioned striatum was markedly reduced compared to the contralateral side (Table  III) .
Discussion
In the present study, we present a model for in uiuo quantitation of high affinity binding sites in brain regions based on the equilibrium distribution of radiolabeled tracers. A major difference between this approach and previous work is recognition of the need to control the regional brain concentrations of free ligand available for subsequent binding. Thus, whereas receptor-mediated tracer distributions have been reported with several labeled ligands for binding sites within the central nervous system, the tracer distribution at a single point in time following bolus systemic injection is representative of receptor density only under select conditions. For example, if the chosen ligand dissociates slowly from the receptor site and the amount of drug injected produces saturating concentrations throughout the brain, the resulting distribution of bound tracer will be relatively unaffected by regional differences in free ligand concentration.
As the time between injection and tissue sampling increases, nonspecific binding decreases as a result of declining plasma levels of the tracer, and high ratios of specific to nonspecific binding may be achieved. Thus, better correlation between receptor density and in uiuo QNB distribution was observed in the original report by Yamamura et al. (1974) , 1982; Gibson et al., 1984) . Furthermore, the higher degree of correlation between receptor density and tracer distribution observed with QNB (Yamamura et al., 1974) than was found in a recent study employing bolus administration of scopolamine (Vora et al., 1983) may be attributable to dissociation of the latter tracer from receptors during the time allowed for washout of nonspecific binding.
In the present study, an infusion protocol producing a constant arterial concentration of tracer was used to allow regional brain pools of free and bound tracer to equilibrate, thus eliminating the effects of cerebral blood flow and regional bloodbrain barrier permeability on the free tissue ligand concentrations which serve as precursor to receptor binding. This experimental approach has resulted in the highest correlation between in uiuo tracer accumulation and regional density of muscarinic receptors yet reported. Whereas the regional densities of in vitro muscarinic receptor binding reported here are in good agreement with previous reports (Yamamura and Snyder, 1974; Kobayashi et al., 1978; Birdsall et al., 1980) , the estimated B,,, values obtained in uiuo are 1.5 times higher than the in vitro measurements.
This unexplained systematic difference between the two measures may reflect the presence of soluble receptors or receptors on tissue fragments too small to be trapped on the filters used for the in vitro assays, degradation of receptors during tissue homogenization, or other postmortem alterations in the tissue samples. The role of muscarinic receptors in the in uiuo distribution of scopolamine is confirmed by the observed effects of removal of striatal binding sites following ibotenic acid lesions. Ibotenic acid or kainic acid lesions of the striatum are known to preferentially effect neurons with cell bodies near the injection site without damaging presynaptic elements from extrinsic neurons, axons of passage, glia, or endothelial elements (Coyle et al., 1978; Murrin et al., 1979; Schwartz et al., 1979) . Lesions of this type result in a marked local reduction in muscarinic receptor density (Schwartz and Coyle, 1977) in the presence of relatively normal levels of cerebral blood flow (Frey and Agranoff, 1983) . The reduction in scopolamine uptake observed in the lesioned striatum thus appears to reflect receptor loss rather than ischemia or other secondary processes. Specific binding of scopolamine in all brain regions examined was saturable. The lowest concentration used, 0.6 pmol/kg, resulted in a saturating plasma concentration of ligand. Lower drug doses were not investigated since the equilibration time for these additional concentrations was expected to exceed the 240-min experimental period used. An upper limit for the in viva affinity of scopolamine for the muscarinic receptor was estimated to be 2 nM. This result is consistent with in vitro estimates of the scopolamine affinity constant obtained in this study, as well as in previous reports (Burgermeister et al., 1978; Hulme et al., 1978; Kloog and Sokolovsky, 1978) .
The specific binding of [3H]scopolamine additionally displayed a pharmacologic profile consistent with the central muscarinic receptor as previously defined in several bioassays. Scopolamine and QNB were more potent inhibitors of binding of the tracer than atropine, and all three were much more -6 -5 -4 -3 effective than methylscopolamine. This rank order is identical to that obtained for elicitation of behavioral changes in the rat (Herz et al., 1965; Parkes, 1965) , mouse (Herz et al., 1965; Parkes, 1965; Rahavi et al., 1978 ), dog (Albanus, 1970 , and human (Ketchum et al., 1973) , as well as EEG alterations in the rabbit (Herz et al., 1965) . These potency differences are LOG lo SCOPOLAMINE, mol/kg presumed to be due to differential permeability of the bloodbrain barrier to the agents (Herz et al., 1965; Weinstein et al., 1977) , which is largely a function of lipid solubility at physiologic pH (Brodie et al., 1960; Rapaport et al., 1979 van der Werf et al. (1983) demonstrated that removal of endogenous dopamine, either by lesions of the substantia nigra or by reserpine treatment, resulted in significant increases in in vivo binding of N-propylnorapomorphine to striatal dopamine receptors. In order to examine possible effects of endogenous acetylcholine (ACh) on in uivo scopolamine binding, we studied a group of animals which had been pretreated with a dose of DFP shown previously to increase ACh in brain (Fonnum and Guttormsen, 1969) and to eliminate histochemical detection of AChE (Fibiger, 1982) . This treatment proved relatively ineffective in altering tracer binding and did not reveal the regional specificity anticipated based on the known heterogeneity of ACh levels and CAT activity (Cheney et al., 1975; Hoover et al., 1978) in the brain regions studied. Although a selective effect on a minor population of binding sites cannot be ruled out, a more parsimonious interpretation is that the saturating tracer concentrations used in the present work competed effectively with synaptic ACh for available receptor sites.
The protracted time course of in uivo scopolamine binding observed at plasma ligand concentrations near 20 nM was unexpected.
Tissue uptake of scopolamine studied at 20 pM levels indicates that nonspecifically bound and free ligand equilibrates rapidly with plasma. Thus, neither blood-brain barrier permeability nor local cerebral blood flow limitations are adequate explanations for the slow equilibration of bound tracer with free tissue and plasma pools. Furthermore, the in vitro kinetics of scopolamine binding indicate rapid association of tracer with the receptor in homogenates (Kloog and Sokolovsky, 1978) .
The observed time courses of in uiuo scopolamine binding are compatible with several interpretations.
First, the kinetics of receptor-ligand interaction under in vivo conditions may differ substantially from the in vitro situation. Modifying effects of substances such as guanine nucleotides and divalent cations or of receptor phosphorylation may differ between intact preparations and tissue homogenates. Reports of antagonist binding to muscarinic receptors on intact cells in culture, however, do not support this speculation (Burgermeister et al., 1978; Frick et al., 1983; Nathanson, 1983) . Second, tracer access to the receptor sites may be restricted in viuo at a point subsequent to extraction from the plasma. If a significant number of receptors are present within a relatively small tissue compartment which is separated from the extracellular space by a diffusion barrier, detection of this compartment would be difficult in the low specific activity infusion experiments, yet its presence could explain the slow time course observed under conditions of high specific activity. This explanation has been proposed to account for observations on the kinetics of in uivo distribution of opiate antagonists, with the speculation that the synaptic cleft may be the anatomic site of the isolated microcompartment (Perry et al., 1980 ). An additional possibility is that the presence of endogenous ACh, bound to receptors and in competition with the tracer for free receptors, retards the rate of tracer binding. The reversal in the pattern of tracer distribution in cortex and striatum observed between 60 and 180 min in the present study may reflect the greater levels of ACh in the striatum competing with [3H]scopolamine. Present evidence does not permit distinction between these possibilities.
The equilibrium model presented here may be applied to a variety of ligands and receptors in vivo. It was validated with the use of radiolabeled scopolamine to measure muscarinic binding. The calculated in. viuo equilibrium distribution of [3H] scopolamine appears to accurately reflect the regional binding capacity for muscarinic antagonists determined by in vitro methods. As predicted by the model, at appropriately chosen ligand concentrations, total tissue tracer levels are proportional to receptor numbers. It is anticipated that this in vivo experimental approach will permit the quantitative autoradiographic localization of receptors in experimental animals, as well as receptor imaging in humans using positron or single-photon emission tomography.
